Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

Cancer Treatment Reviews

Volumn 48, Issue , 2016, Pages 8-19

  Macerelli, Marianna ^a   Ganzinelli, Monica ^a   Gouedard, Cedric ^b   Broggini, Massimo ^c   Garassino, Marina Chiara ^a   Linardou, Helena ^d   Damia, Giovanna ^c   Wiesmüller, Lisa ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ATHENS   (Greece)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d METROPOLITAN HOSPITAL   (Greece)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Biomarker; DNA repair; Non small cell lung cancer; Platinum agents

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA PROTEIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DNA CROSS LINKING; DNA REPAIR; DNA REPLICATION; DRUG RESPONSE; ERCC1 GENE; EX VIVO STUDY; EXCISION REPAIR; GENE EXPRESSION; HUMAN; LIQUID BIOPSY; META ANALYSIS (TOPIC); MISMATCH REPAIR; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINATION REPAIR; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC); TRANSLESION SYNTHESIS; TUMOR BIOPSY; GENETICS; LUNG TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 84973624944     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.05.004     Document Type: Review

References (181)

1. Couch F.J., Nathanson K.L., Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014, 343:1466-1470.
2. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012, 12:801-817.
3. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50:6119-6129.
4. Khanna A. DNA damage in cancer therapeutics: a boon or a curse?. Cancer Res 2015, 75:2133-2138.
5. Ceccaldi R., Rondinelli B., D'Andrea A.D. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 2015.
6. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
7. Damia G., D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007, 43:1791-1801.
8. Damia G., Imperatori L., Stefanini M., D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996, 66:779-783.
9. Deans A.J., West S.C. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011, 11:467-480.
10. Darzynkiewicz Z., Traganos F., Wlodkowic D. Impaired DNA damage response - an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009, 625:143-150.
11. Dai C.H., Li J., Chen P., Jiang H.G., Wu M., Chen Y.C. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. J Biomed Sci 2015, 22:77.
12. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012, 30:2654-2663.
13. Tan D.S., Rothermundt C., Thomas K., Bancroft E., Eeles R., Shanley S., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-5536.
14. Berwick M., Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000, 92:874-897.
15. Ralhan R., Kaur J., Kreienberg R., Wiesmuller L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett 2007, 248:1-17.
16. Jalal S., Earley J.N., Turchi J.J. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011, 17:6973-6984.
17. Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D'Andrea A.D. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015.
18. Guidugli L., Carreira A., Caputo S.M., Ehlen A., Galli A., Monteiro A.N., et al. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat 2014, 35:151-164.
19. Millot G.A., Carvalho M.A., Caputo S.M., Vreeswijk M.P., Brown M.A., Webb M., et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 2012, 33:1526-1537.
20. Varga D., Deniz M., Schwentner L., Wiesmuller L. Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci 2013, 14:640-673.
21. Hutchinson L. Chemotherapy: DNA repair predicts survival in patients with NSCLC. Nat Rev Clin Oncol 2011, 8:627.
22. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999, 99:2467-2498.
23. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
24. Aguilera A., Gomez-Gonzalez B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet 2008, 9:204-217.
25. Haynes B., Saadat N., Myung B., Shekhar M.P. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res 2015, 763:258-266.
26. Galluzzi L., Vitale I., Michels J., Brenner C., Szabadkai G., Harel-Bellan A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014, 5:e1257.
27. Ho T.V., Scharer O.D. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Mol Mutagen 2010, 51:552-566.
28. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000, 60:1305-1313.
29. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
30. Welsh C., Day R., McGurk C., Masters J.R., Wood R.D., Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110:352-361.
31. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
32. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368:1101-1110.
33. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
34. Zhang Q., Zhu X., Zhang L., Sun S., Huang J., Lin Y. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2014, 74:839-846.
35. Novello S., Grohé C., Geissler M., Kurapati M.M.S., Colantonio I. Preliminary results of the international tailored chemotherapy adjuvant trial: the ITACA trial. J Thorac Oncol 2015, 10:S179.
36. He Y.W., Zhao M.L., Yang X.Y., Zeng J., Deng Q.H., He J.X. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer. Cancer Chemother Pharmacol 2015, 75:861-867.
37. Simon G.R., Sharma S., Cantor A., Smith P., Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983.
38. Tseden-Ish M., Choi Y.D., Cho H.J., Ban H.J., Oh I.J., Kim K.S., et al. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Respirology 2012, 17:127-133.
39. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808.
40. Lee K.H., Min H.S., Han S.W., Oh D.Y., Lee S.H., Kim D.W., et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60:401-407.
41. Okuda K., Sasaki H., Dumontet C., Kawano O., Yukiue H., Yokoyama T., et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008, 62:105-112.
42. Choi C.M., Yang S.C., Jo H.J., Song S.Y., Jeon Y.J., Jang T.W., et al. Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol 2012, 23:2088-2093.
43. Pierceall W.E., Olaussen K.A., Rousseau V., Brambilla E., Sprott K.M., Andre F., et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012, 23:2245-2252.
44. Chen S., Zhang J., Wang R., Luo X., Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, 70:63-70.
45. Hubner R.A., Riley R.D., Billingham L.J., Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS ONE 2011, 6:e25164.
46. Roth J.A., Carlson J.J. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2011, 12:393-401.
47. Gandara D.R., Kawaguchi T., Crowley J., Moon J., Furuse K., Kawahara M., et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009, 27:3540-3546.
48. Wei H.B., Hu J., Shang L.H., Zhang Y.Y., Lu F.F., Wei M., et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2012, 125:2902-2907.
49. Wei S.Z., Zhan P., Shi M.Q., Shi Y., Qian Q., Yu L.K., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011, 28:315-321.
50. Yu D., Shi J., Sun T., Du X., Liu L., Zhang X., et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol 2012, 33:877-884.
51. Tiseo M., Bordi P., Bortesi B., Boni L., Boni C., Baldini E., et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 2013, 108:1695-1703.
52. Qin Q., Zhang C., Yang X., Zhu H., Yang B., Cai J., et al. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PLoS ONE 2013, 8:e79864.
53. Li P., Wang Y.D., Cheng J., Chen J.C., Ha M.W. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen. Tumour Biol 2015.
54. Liu L., Wu J., Zhong R., Wu C., Zou L., Yang B., et al. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog 2013, 52:923-931.
55. Wang L.E., Yin M., Dong Q., Stewart D.J., Merriman K.W., Amos C.I., et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011, 29:4121-4128.
56. Thompson L.H., Hinz J.M. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 2009, 668:54-72.
57. Kennedy R.D., D'Andrea A.D. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005, 19:2925-2940.
58. Salehan M.R., Morse H.R. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 2013, 70:31-40.
59. Goodman M.F., Woodgate R. Translesion DNA polymerases. Cold Spring Harb Perspect Biol 2013, 5:a010363.
60. White R.R., Sung P., Vestal C.G., Benedetto G., Cornelio N., Richardson C. Double-strand break repair by interchromosomal recombination: an in vivo repair mechanism utilized by multiple somatic tissues in mammals. PLoS ONE 2013, 8:e84379.
61. Rosell R., Skrzypski M., Jassem E., Taron M., Bartolucci R., Sanchez J.J., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2:e1129.
62. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
63. Boukovinas I., Papadaki C., Mendez P., Taron M., Mavroudis D., Koutsopoulos A., et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 2008, 3:e3695.
64. Harada H., Miyamoto K., Yamashita Y., Nakano K., Taniyama K., Miyata Y., et al. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer 2013, 119:792-798.
65. Lee S.Y., Kang H.G., Yoo S.S., Kang Y.R., Choi Y.Y., Lee W.K., et al. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 2013, 82:330-339.
66. Bonanno L., Costa C., Majem M., Sanchez J.J., Gimenez-Capitan A., Rodriguez I., et al. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget 2013, 4:1572-1581.
67. Bonanno L., Costa C., Majem M., Favaretto A., Rugge M., Rosell R. The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Ann Oncol 2013, 24:1130-1132.
68. Jiang Y.H., Xu X.L., Ruan H.H., Xu W.Z., Li D., Feng J.G., et al. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer. Med Oncol 2014, 31:959.
69. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262.
70. Howlett N.G., Taniguchi T., Durkin S.G., D'Andrea A.D., Glover T.W. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005, 14:693-701.
71. Birkelbach M., Ferraiolo N., Gheorghiu L., Pfaffle H.N., Daly B., Ebright M.I., et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013, 8:279-286.
72. Gagou M.E., Zuazua-Villar P., Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010, 21:739-752.
73. Neal J.W., Sequist L.V. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol 2010, 8:119-126.
74. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
75. Pfaffle H.N., Wang M., Gheorghiu L., Ferraiolo N., Greninger P., Borgmann K., et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res 2013, 73:6254-6263.
76. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005, 280:31182-31189.
77. Liccardi G., Hartley J.A., Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011, 71:1103-1114.
78. Patterson M.J., Sutton R.E., Forrest I., Sharrock R., Lane M., Kaufmann A., et al. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br J Cancer 2014, 111:94-100.
79. Wang W., Sheng W., Yu C., Cao J., Zhou J., Wu J., et al. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. Oncol Rep 2015, 34:1460-1468.
80. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006, 7:335-346.
81. Mello J.A., Acharya S., Fishel R., Essigmann J.M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996, 3:579-589.
82. O'Brien V., Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006, 27:682-692.
83. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
84. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56:4881-4886.
85. Kamal N.S., Soria J.C., Mendiboure J., Planchard D., Olaussen K.A., Rousseau V., et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16:1206-1215.
86. Zalcman G. A DNA-repair prognostic signature for early-stage NSCLC patients, in IFCT-0002 trial of neoadjuvant chemotherapy. J Clin Oncol 2013, 31. abstr 7515.
87. Vageli D.P., Zaravinos A., Daniil Z., Dahabreh J., Doukas S.G., Spandidos D.A., et al. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment. Int J Biol Markers 2012, 27. e400-4.
88. Scartozzi M., Franciosi V., Campanini N., Benedetti G., Barbieri F., Rossi G., et al. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006, 53:103-109.
89. Olaussen K.A., Adam J., Vanhecke E., Vielh P., Pirker R., Friboulet L., et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer 2013, 80:216-222.
90. Xie K.J., He H.E., Sun A.J., Liu X.B., Sun L.P., Dong X.J. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev 2014, 15:2591-2596.
91. Wang D., Xiang D.B., Yang X.Q., Chen L.S., Li M.X., Zhong Z.Y., et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
92. Peng Y., Li Z., Zhang S., Xiong Y., Cun Y., Qian C., et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer 2014, 135:2687-2696.
93. Fikrova P., Stetina R., Hrnciarik M., Hrnciarikova D., Hronek M., Zadak Z. DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives. Oncol Rep 2014, 31:391-396.
94. Gackowski D., Speina E., Zielinska M., Kowalewski J., Rozalski R., Siomek A., et al. Products of oxidative DNA damage and repair as possible biomarkers of susceptibility to lung cancer. Cancer Res 2003, 63:4899-4902.
95. Caiola E., Salles D., Frapolli R., Lupi M., Rotella G., Ronchi A. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget 2015.
96. Nicolay N.H., Helleday T., Sharma R.A. Biological relevance of DNA polymerase beta and translesion synthesis polymerases to cancer and its treatment. Curr Mol Pharmacol 2012, 5:54-67.
97. Yap T.A., Lorente D., Omlin A., Olmos D., de Bono J.S. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014, 20:2553-2568.
98. Truini A., Alama A., Dal Bello M.G., Coco S., Vanni I., Rijavec E., et al. Clinical applications of circulating tumor cells in lung cancer patients by cell search system. Front Oncol 2014, 4:242.
99. Das M., Riess J.W., Frankel P., Schwartz E., Bennis R., Hsieh H.B., et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012, 77:421-426.
100. Nel I., Gauler T.C., Eberhardt W.E., Nickel A.C., Schuler M., Thomale J., et al. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer 2013, 109:1223-1229.
101. Dai N., Cao X.J., Li M.X., Qing Y., Liao L., Lu X.F., et al. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer. PLoS ONE 2013, 8:e58001.
102. Higashiyama M., Oda K., Okami J., Maeda J., Kodama K., Imamura F., et al. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer 2010, 68:472-477.
103. Baty F., Facompre M., Kaiser S., Schumacher M., Pless M., Bubendorf L., et al. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Respir Crit Care Med 2010, 181:181-188.
104. Xian-Jun F., Xiu-Guang Q., Li Z., Hui F., Wan-Ling W., Dong L., et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pak J Med Sci 2014, 30:488-492.
105. Wang T.B., Zhang N.L., Wang S.H., Li H.Y., Chen S.W., Zheng Y.G. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy. Genet Mol Res 2014, 13:3704-3710.
106. Li Y., Wang L.R., Chen J., Lou Y., Zhang G.B. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. Dis Markers 2014, 2014:960458.
107. Leng X.F., Chen M.W., Xian L., Dai L., Ma G.Y., Li M.H. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res 2012, 31:25.
108. Zhang G.B., Chen J., Wang L.R., Li J., Li M.W., Xu N., et al. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2012, 69:1277-1287.
109. Su C., Zhou S., Zhang L., Ren S., Xu J., Zhang J., et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2011, 28:1411-1417.
110. Li J., Li Z.N., Yu L.C., Bao Q.L., Wu J.R., Shi S.B., et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 2010, 69:116-122.
111. Han X.P. Zhang X. Zhonghua Yi Xue Za Zhi 2010, 90:2115-2118.
112. Ren S., Zhou S., Zhang L., Xu J., Lv M., Zhang J., et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 2010, 28:1078-1083.
113. Li X.Q., Li J., Shi S.B., Chen P., Yu L.C., Bao Q.L. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 2009, 24:230-237.
114. Li J., Li Z.N., Du Y.J., Li X.Q., Bao Q.L., Chen P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 2009, 10:414-421.
115. Qian X.P., Liu B.R., Shi M.Q., Liu X.Z., Hu W.J., Zou Z.Y. Et al. Zhonghua Zhong Liu Za Zhi 2009, 31:33-37.
116. Kotoula V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A.G., Televantou D., et al. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer 2012, 12:342.
117. Pesta M., Kulda V., Fiala O., Safranek J., Topolcan O., Krakorova G., et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 2012, 32:5003-5010.
118. Papadaki C., Sfakianaki M., Ioannidis G., Lagoudaki E., Trypaki M., Tryfonidis K., et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:663-671.
119. Joerger M., deJong D., Burylo A., Burgers J.A., Baas P., Huitema A.D., et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011, 74:310-317.
120. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:902-906.
121. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
122. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
123. Rosell R., Felip E., Taron M., Majo J., Mendez P., Sanchez-Ronco M., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10:4215s-4219s.
124. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
125. Tantraworasin A., Saeteng S., Lertprasertsuke N., Arayawudhikul N., Kasemsarn C., Patumanond J. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res 2013, 5:327-336.
126. Yan D., Wei P., An G., Chen W. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg 2013, 8:149.
127. Yokomise H., Liu D., Chang S., Go T., Ishikawa S., Misaki N., et al. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 2013, 33:1107-1115.
128. Zhang L., Liu T. Zhang JQ. Zhonghua Zhong Liu Za Zhi 2011, 33:212-216.
129. Li G.F., Deng S.J., Weng W.W., Guo G. Chen N. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:2131-2133.
130. Huang C.L., Kadota K., Liu D., Ueno M., Nakasima N., Ishikawa S., et al. Expression of ERCC1 and class III beta-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Exp Ther Med 2010, 1:445-451.
131. Zhang S., Li Q., Zhang Q., Wang J., Zhang H., Zhang Z., et al. Expression of ERCC1 and class III ss-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy. Int J Biol Markers 2010, 25:141-149.
132. Wang X., Zhao J., Yang L., Mao L., An T., Bai H., et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 2010, 27:484-490.
133. Kang C.H., Jang B.G., Kim D.W., Chung D.H., Kim Y.T., Jheon S., et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010, 68:478-483.
134. Jeong S.H., Jung J.H., Han J.H., Kim J.H., Choi Y.W., Lee H.W., et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 2010, 68:288-294.
135. Ikeda S., Takabe K., Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009, 59:863-867.
136. Lee H.W., Choi Y.W., Han J.H., Kim J.H., Jung J.H., Jeong S.H., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009, 65:377-382.
137. Azuma K., Sasada T., Kawahara A., Hattori S., Kinoshita T., Takamori S., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009, 64:565-573.
138. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326-333.
139. Ota S., Ishii G., Goto K., Kubota K., Kim Y.H., Kojika M., et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64:98-104.
140. Hwang I.G., Ahn M.J., Park B.B., Ahn Y.C., Han J., Lee S., et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113:1379-1386.
141. Fujii T., Toyooka S., Ichimura K., Fujiwara Y., Hotta K., Soh J., et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008, 59:377-384.
142. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007, 98:1336-1343.
143. Huang P.Y., Liang X.M., Lin S.X., Luo R.Z., Hou J.H., Zhang L. Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Ai Zheng 2004, 23:845-850.
144. Sad L.M., Younis S.G., Elity M.M. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. Med Oncol 2014, 31:58.
145. Toffart A.C., Timsit J.F., Couraud S., Merle P., Moro-Sibilot D., Perol M., et al. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 2014, 83:182-188.
146. Vassalou H., Stathopoulos E., Fiolitaki G., Koutsopoulos A., Voutsina A., Georgoulias V., et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 2013, 82:324-329.
147. Cubukcu E., Fatih Olmez O., Saraydaroglu O., Akcali U., Kanat O., Kurt E., et al. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome. Clin Transl Oncol 2011, 13:826-830.
148. Bepler G., Olaussen K.A., Vataire A.L., Soria J.C., Zheng Z., Dunant A., et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 2011, 178:69-78.
149. Vilmar A.C., Santoni-Rugiu E., Sorensen J.B. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, 21:1817-1824.
150. Holm B., Mellemgaard A., Skov T., Skov B.G. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009, 27:4254-4259.
151. Jiang J., Liang X., Zhou X., Huang R., Chu Z., Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 2012, 39:6933-6942.
152. Lv H., Han T., Shi X., Yao Y., Qiu W., Yue L., et al. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol 2014, 31:86.
153. Du Y., Su T., Zhao L., Tan X., Chang W., Zhang H., et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS ONE 2014, 9:e99843.
154. Huang S.J., Wang Y.F., Jin Z.Y., Sun J.Y., Guo Z.L. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour Biol 2014, 35:4023-4029.
155. Hong W., Wang K., Zhang Y.P., Kou J.Y., Hong D., Su D., et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J Zhejiang Univ Sci B 2013, 14:207-215.
156. Zhang Z.Y., Tian X., Wu R., Liang Y., Jin X.Y. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2012, 13:2583-2586.
157. Liao W.Y., Shih J.Y., Chang G.C., Cheng Y.K., Yang J.C., Chen Y.M., et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 2012, 7:973-981.
158. Li D., Zhou Q., Liu Y., Yang Y., Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 2012, 29:1622-1628.
159. Ren S., Zhou S., Wu F., Zhang L., Li X., Zhang J., et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 2012, 75:102-109.
160. Cheng J., Ha M., Wang Y., Sun J., Chen J., Tong C. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2012, 138:231-238.
161. Okuda K., Sasaki H., Hikosaka Y., Kawano O., Yukiue H., Yano M., et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 2011, 168:206-212.
162. Shiraishi K., Kohno T., Tanai C., Goto Y., Kuchiba A., Yamamoto S., et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010, 28:4945-4952.
163. Wang J., Zhang Q., Zhang H., Wang Q., Yang X., Gu Y., et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Zhongguo Fei Ai Za Zhi 2010, 13:337-341.
164. Li F., Sun X., Sun N., Qin S., Cheng H., Feng J., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, 33:489-494.
165. Su D., Ma S., Liu P., Jiang Z., Lv W., Zhang Y., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56:281-288.
166. Park S.Y., Hong Y.C., Kim J.H., Kwak S.M., Cho J.H., Lee H.L., et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 2006, 23:489-498.
167. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
168. Krawczyk P., Wojas-Krawczyk K., Mlak R., Kucharczyk T., Biernacka B., Milanowski J. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer - a pilot study. Folia Histochem Cytobiol 2012, 50:80-86.
169. Joerger M., Burgers S.A., Baas P., Smit E.F., Haitjema T.J., Bard M.P., et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012, 118:2466-2475.
170. Ludovini V., Floriani I., Pistola L., Minotti V., Meacci M., Chiari R., et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 2011, 6:2018-2026.
171. Vinolas N., Provencio M., Reguart N., Cardenal F., Alberola V., Sanchez-Torres J.M., et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011, 71:191-198.
172. Metro G., Chiari R., Mare M., Giannarelli D., Tofanetti F.R., Minotti V., et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 2011, 68:1405-1412.
173. Kalikaki A., Kanaki M., Vassalou H., Souglakos J., Voutsina A., Georgoulias V., et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:118-123.
174. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
175. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.
176. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
177. Huang D., Zhou Y. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep 2014, 2:452-462.
178. Xu T.P., Shen H., Liu L.X., Shu Y.Q. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 2013, 526:265-274.
179. Yin M., Yan J., Voutsina A., Tibaldi C., Christiani D.C., Heist R.S., et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 2011, 72:370-377.
180. KimCurran V., Zhou C., Schmid-Bindert G., Shengxiang R., Zhou S., Zhang L., et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci 2011, 56:30-38.
181. Iranzo V., Sirera R., Bremnes R.M., Blasco A., Jantus-Lewintre E., Taron M., et al. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clin Lung Cancer 2011, 12:224-230.